Opthea Pty Ltd is a private, 100% owned subsidiary of Circadian Technologies Limited based in Melbourne, Australia.

Opthea is developing novel biologic inhibitors of angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth) and vascular leakage for the treatment of ophthalmic diseases.

Opthea has received seed funding from Circadian Technologies and is actively seeking partnership opportunities and investment for its development programs.  Enquiries can be directed to: info@opthea.com


Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY), through its 100% owned subsidiary Opthea P Read More...

Circadian Technologies (ASX:CIR; OTCQX:CKDXY), through its 100% owned subsidiary Opthea Pty Ltd ( Read More...

Please find below a link to Circadian’s updated company profile for the October edition of Read More...


To receive notifications about Opthea, subscribe to our distribution list.